Is compounded semaglutide still legal in 2026?
Routine shortage-based copying of semaglutide ended after the FDA resolved the shortage. Learn when patient-specific compounding may still occur and what to verify.
Written and fact-checked by ClearlyMeds Editorial Team. Published July 18, 2026. Last updated July 18, 2026.
This page has not been medically reviewed by a licensed clinician. It is educational content, not medical advice.
Compounded semaglutide is not categorically illegal in 2026, but the broad shortage-based pathway for making routine copies ended after the FDA resolved the semaglutide injection shortage. A licensed prescriber and qualifying pharmacy may still compound for a documented patient-specific clinical need under applicable law. Compounded products are not FDA approved.
What changed after the shortage
During the shortage, federal policy allowed more compounding activity because approved products were not consistently available. The FDA later determined that the shortage was resolved and ended its temporary enforcement-discretion periods. That means a pharmacy generally cannot keep mass-producing a product that is essentially a copy merely because it is cheaper or popular.
When compounding may still be allowed
Federal compounding law contains patient-specific pathways and other limited circumstances. Whether a particular prescription qualifies depends on the prescriber, pharmacy type, formulation, clinical difference, and state and federal rules. ClearlyMeds does not treat a provider's “customized” label as proof that the prescription is lawful or medically necessary.
What patients should verify
Ask for the dispensing pharmacy's name, whether it is state licensed or an FDA-registered outsourcing facility, why the compounded version is clinically different for you, and how adverse events are handled. Avoid products sold as research chemicals or without a prescription. The FDA has warned about dosing errors, fraudulent labels, and salt forms that differ from the active ingredient in approved products.
ClearlyMeds bottom line
Patient-specific compounding can still exist, but routine shortage-era copying is no longer the default legal pathway. Because the product is not FDA approved, pharmacy identity, prescription rationale, dose instructions, and follow-up matter. Verify those facts before paying a telehealth program.
Compounded semaglutide status in 2026
| Scenario | General status | What to verify |
|---|---|---|
| Routine shortage-based copy | Temporary discretion ended | Do not assume the old shortage rule still applies |
| Patient-specific clinical need | May qualify under compounding law | Documented rationale and pharmacy pathway |
| FDA approval | Not approved | Quality is not pre-reviewed like an approved drug |
| Research product sold for injection | Not an approved prescription drug | Avoid unverified sellers |
Related provider reviews
ClearlyMeds connects this answer to the provider reviews most relevant to the decision.
Sources
- FDA clarifies policies for compounders as national GLP-1 supply stabilizes — U.S. Food and Drug Administration
- FDA concerns with unapproved GLP-1 drugs used for weight loss — U.S. Food and Drug Administration
Frequently asked questions
Did the FDA ban all compounded semaglutide?
No. The FDA ended temporary shortage-based enforcement discretion, but patient-specific compounding may still occur when legal requirements are met.
Is compounded semaglutide FDA approved?
No. Compounded drugs are not FDA approved, and the FDA does not pre-review them for safety, effectiveness, or quality in the same way.
What pharmacy information should a telehealth provider disclose?
Patients should be able to identify the dispensing pharmacy, verify its licensing or registration, and receive written dose and follow-up instructions.